Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate

被引:77
作者
Jenssen, H [1 ]
Andersen, JH
Uhlin-Hansen, L
Gutteberg, TJ
Rekdal, O
机构
[1] Univ Hosp N Norway, Dept Med Microbiol, N-9038 Tromso, Norway
[2] Univ Hosp N Norway, Dept Pathol, N-9038 Tromso, Norway
[3] Univ Tromso, Med Biol Inst, Dept Biochem, N-9037 Tromso, Norway
关键词
lactoferricin; antiviral activity; herpes simplex virus; heparan sulfate; structure-activity relation;
D O I
10.1016/j.antiviral.2003.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Earlier studies have shown that the heparan sulfate (HS) on the cell surface acts as a receptor for herpes simplex virus (HSV). We have recently shown that bovine lactoferricin (LfcinB), a small part of the milk protein lactoferrin, inhibits HSV-1 and HSV-2 infection, probably by blocking the entry of the virus. The human homologue (18-42), which shares 36% sequence similarity with LfcinB (17-41), displayed much lower antiviral activity. In the present study, a set of cyclic and linear human and bovine Lfcin derivatives were constructed to investigate the relation between their affinity to HS and chondroitin sulfate (CS) and their antiviral activity against HSV-1 and HSV-2. The lactoferrin (LF) proteins and several of the Lfcin derivatives exhibited similar affinity for HS, but the LF proteins possess a much higher antiviral activity than the smaller peptides. Our structure-activity relationship studies on the Lfcin derivates confirmed that affinity for HS, that was correlated to the net positive charge, is an important factor, but does not well predict the antiviral activity. Structural parameters such as hydrophobicity, molecular size, spatial distribution of charged and lipophilic amino acids, and the cyclic structure of Lfcin also seem to be important factors to govern antiviral activity against HSV. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 43 条
[1]   Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir [J].
Andersen, JH ;
Jenssen, H ;
Gutteberg, TJ .
ANTIVIRAL RESEARCH, 2003, 58 (03) :209-215
[2]   Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts [J].
Andersen, JH ;
Osbakk, SA ;
Vorland, LH ;
Traavik, T ;
Gutteberg, TJ .
ANTIVIRAL RESEARCH, 2001, 51 (02) :141-149
[3]  
ANDERSEN JH, 2002, 28 INT HERP WORKSH C
[4]   EVIDENCE FOR AN INTERACTION OF HERPES-SIMPLEX VIRUS WITH CHONDROITIN SULFATE PROTEOGLYCANS DURING INFECTION [J].
BANFIELD, BW ;
LEDUC, Y ;
ESFORD, L ;
VISALLI, RJ ;
BRANDT, CR ;
TUFARO, F .
VIROLOGY, 1995, 208 (02) :531-539
[5]   ANTIBACTERIAL SPECTRUM OF LACTOFERRICIN-B, A POTENT BACTERICIDAL PEPTIDE DERIVED FROM THE N-TERMINAL REGION OF BOVINE LACTOFERRIN [J].
BELLAMY, W ;
TAKASE, M ;
WAKABAYASHI, H ;
KAWASE, K ;
TOMITA, M .
JOURNAL OF APPLIED BACTERIOLOGY, 1992, 73 (06) :472-479
[6]   MOLECULAR MODELING OF PROTEIN-GLYCOSAMINOGLYCAN INTERACTIONS [J].
CARDIN, AD ;
WEINTRAUB, HJR .
ARTERIOSCLEROSIS, 1989, 9 (01) :21-32
[7]   CONTROVERSIAL GLYCOSAMINO-GLYCAN CONFORMATIONS [J].
CASU, B ;
CHOAY, J ;
FERRO, DR ;
GATTI, G ;
JACQUINET, JC ;
PETITOU, M ;
PROVASOLI, A ;
RAGAZZI, M ;
SINAY, P ;
TORRI, G .
NATURE, 1986, 322 (6076) :215-216
[8]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[9]   The binding of lactoferrin to glycosaminoglycans on enterocyte-like HT29-18-C1 cells is mediated through basic residues located in the N-terminus [J].
El Yazidi-Belkoura, I ;
Legrand, D ;
Nuijens, J ;
Slomianny, MC ;
van Berkel, P ;
Spik, G .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1568 (03) :197-204
[10]  
Hammer J, 2000, INT CONGR SER, V1195, P239